glp-1 shortage news today 2025 Receptor Agonist Market Size & Trends 2035 glp-1 shortage news today 2025

Wright AK, Carr MJ, Kontopantelis E, Leelarathna L, Thabit H, Emsley R, et al

Those engaging in physical activity, living in hot climates, or experiencing increased urination (common with hyperglycemia or SGLT2 inhibitor medications) require additional hydration beyond baseline recommendations

These findings underscore the importance of identifying dosedependent and circuitspecific mechanisms in humans, as differential engagement of stressrelated versus rewardrelated neural pathways may help explain the heterogeneous anxietyrelated outcomes observed in clinical settings

Although the vast majority of patients achieve desired results, there is no guarantee of results for any treatment

Key Mergers and Acquisitions January 2026: Eli Lilly and Company acquired a biotech firm developing next-generation dual GLP-1/GIP agonists to expand its obesity and diabetes portfolio beyond Mounjaro and Zepbound